Predictive and prognostic value of circulating nucleosomes and serum biomarkers in patients with metastasized colorectal cancer undergoing Selective Internal Radiation Therapy

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Fahmueller, Yvonne N ^a   Nagel, Dorothea ^a   Hoffmann, Ralf Thorsten ^a,b   Tatsch, Klaus ^a,c   Jakobs, Tobias ^a,d   Stieber, Petra ^a   Holdenrieder, Stefan ^a,e  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c Municipial Hospital Karlsruhe   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Cancer biomarker; Colorectal cancer; Nucleosomes; Selective internal radiation therapy; Therapy response

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMYLASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; FLUOROURACIL; FOLINIC ACID; GAMMA GLUTAMYLTRANSFERASE; IRINOTECAN; OXALIPLATIN; TUMOR ANTIGEN; MEDRONATE TECHNETIUM TC 99M; RADIOPHARMACEUTICAL AGENT; TUMOR MARKER;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD SAMPLING; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; COHORT ANALYSIS; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; LIVER METASTASIS; MALE; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEOSOME; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PROSPECTIVE STUDY; SELECTIVE INTERNAL RADIATION THERAPY; BLOOD; COLORECTAL TUMOR; KAPLAN MEIER METHOD; LIVER TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE; PROGNOSIS; SURVIVAL;

ADULT; AGED; COHORT STUDIES; COLORECTAL NEOPLASMS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NUCLEOSOMES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; SURVIVAL ANALYSIS; TECHNETIUM TC 99M MEDRONATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84855289654     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-5     Document Type: Article

References (50)

1. Parkin D, Bray F, Ferlay J, Pisani P. Global Cancer Statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
2. American Cancer Society Cancer Facts & Figures 2009. 2009, Atlanta: American Cancer Society, American Cancer Society.
3. Scheele J, Stanl R, Altendorf-Hoffmann A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg 1990, 77:1241-1246.
4. Weiss L, Grundmann E, Torhorst J, Hartveit F, Moberg I, Eder M, Fenoglio-Preiser CM, Napier J, Horne CH, Lopez MJ. Haematogenous metastases patterns in colonic carcinoma: an analysis of 1541 necropsies. J Pathol 1986, 150:195-203.
5. Ruers T, Bleichrodt RP. Treatment of liver metastases. an update on the possibilities and results. Eur J Cancer 2002, 38:1023-1033.
6. Seifert JK, Morris DL. Prognostic factors after cryotherapy for hepatic metastases from colorectal cancer. Ann Surg 1998, 228:201-208.
7. Bilchik AJ, Wood TF, Allegra DP. Radiofrequency ablation of unresectable hepatic malignancies: lessons learned. Oncol 2001, 6:24-33.
8. Dawson LA, Ten Haken RK, Lawrence TS. Partial irradiation of the liver. Semin Radiat Oncol 2001, 11:240-246.
9. Breedis C, Young G. The blood supply of neoplasms in the liver. Am J Pathol 1954, 30:969-977.
10. Campbell AM, Bailey IH, Burton MA. Tumor dosimetry in human liver following hepatic yttrium-90 microsphere therapy. Phys Med Biol 2001, 46:487-498.
11. Kennedy AS, Nutting C, Coldwell D, Gaiser J, Drachenberg C. Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys 2004, 60:1552-1563.
12. Van Hazel G, Blackwell A, Anderson J, Price D, Moroz P, Bower G, Cardaci G, Gray B. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol 2004, 88:78-85.
13. Wollner IS, Knutsen CA, Ullrich KA, Chrisp CE, Juni JE, Andrews JC, Tuscan MJ, Stetson PL, Ensminger WD. Effects of hepatic arterial yttrium-90 microsphere administration alone and combined with regional bromodeoxyuridine infusion in dogs. Cancer Res 1987, 47:3285-3290.
14. Konda A, Savin MA, Cappell MS, Duffy MC. Radiation microsphere-induced GI ulcers after selective internal radiation therapy for hepatic tumors: an underrecognized clinical entity. Gastrointest Endosc 2009, 70:561-567.
15. Leung TW, Lau WY, Ho SK, Ward SC, Chow JH, Chan MS, Metreweli C, Johnson PJ, Li AK. Radiation pneumonitis after selective internal radiation treatment with intraarterial 90yttrium-microspheres for inoperable hepatic tumors. Int J Radiat Oncol Biol Phys 1995, 33:919-924.
16. Jakobs TF, Hoffmann RT, Poepperl G, Schmitz A, Lutz J, Koch W, Tatsch K, Lubiensky A, Reiser MF, Helmberger T. Mid-term results in otherwise treatment refractory primary or secondary liver confined tumours treated with selective internal radiation therapy (SIRT) using (90)Yttrium resin-microspheres. Eur Radiol 2007, 17:1320-1330.
17. Ho S, Lau WY, Leung TW, Chan M, Chan KW, Lee WY, Johnson PJ, Li AK. Tumour-to-normal uptake ratio of 90Y microspheres in hepatic cancer assessed with 99Tcm macroaggregated albumin. Br J Radiol 1997, 70:823-828.
18. Dunfee BL, Riaz A, Lewandowski RJ, Ibrahim S, Mulcahy MF, Ryu RK, Atassi B, Sato KT, Newman S, Omary RA, Benson A, Salem R. Yttrium-90 radioembolization for liver malignancies: prognostic factors associated with survival. J Vasc Interv Radiol 2010, 21:90-95.
19. Holdenrieder S, Stieber P, von Pawel J, Raith H, Nagel D, Feldmann K, Seidel D. Circulating nucleosomes predict the response to chemotherapy in patients with advanced non small cell lung cancer. Clin Cancer Res 2004, 10:5981-5987.
20. Holdenrieder S, von Pawel J, Dankelmann E, Duell T, Faderl B, Markus A, Siakavara M, Wagner H, Feldmann K, Hoffmann H, Raith H, Nagel D, Stieber P. Nucleosomes, ProGRP, NSE, CYFRA 21-1 and CEA in the therapy monitoring of small-cell lung cancer during first-line chemotherapy. Clin Cancer Res 2008, 14:7813-7821.
21. Holdenrieder S, Stieber P, von Pawel J, Raith H, Nagel D, Feldmann K, Seidel D. Early and specific prediction of the therapeutic efficacy in lung cancer by nucleosomal DNA and cytokeratin 19 fragments. Ann N Y Acad Sci 2006, 1075:244-275.
22. Holdenrieder S, von Pawel J, Dankelmann E, Duell T, Faderl B, Markus A, Siakavara M, Wagner H, Feldmann K, Hoffmann H, Raith H, Nagel D, Stieber P. Nucleosomes and CYFRA 21-1 indicate tumor response after one cycle of chemotherapy in recurrent non-small cell lung cancer. Lung Cancer 2009, 63:128-135.
23. Holdenrieder S, Stieber P. Clinical use of circulating nucleosomes. Crit Rev Clin Lab Sci 2009, 46:1-24.
24. Kremer A, Wilkowski R, Holdenrieder S, Nagel D, Stieber P, Seidel D. Nucleosomes in pancreatic cancer patients during radiochemotherapy. Tumor Biol 2005, 26:44-49.
25. Kremer A, Holdenrieder S, Stieber P, Wilkowski R, Nagel D, Seidel D. Nucleosomes in colorectal cancer patients during radiochemotherapy. Tumor Biol 2006, 27:235-242.
26. Holdenrieder S, Holubec L, Topolcan O, Finek J, Stieber P. Circulating nucleosomes and cytokeratin 19-fragments in patients with colorectal cancer during chemotherapy. Anticancer Res 2005, 25:1795-1801.
27. De Haas RJ, Wicherts DA, Flores E, Ducreux M, Lévi F, Paule B, Azoulay D, Castaing D, Lemoine A, Adam R. Tumor marker evolution: comparison with imaging for assessment of response to chemotherapy in patients with colorectal liver metastases. Ann Surg Oncol 2010, 17:1010-1023.
28. Jakobs TF, Hoffmann RT, Tatsch K, Trumm C, Reiser MF, Helmberger TK. Developments and perspectives in radioablative techniques. Radiol 2007, 47:1083-1088.
29. Weber WA. Assessing tumor response to therapy. J Nucl Med 2009, 50:S1-10.
30. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000, 92:205-216.
31. Holdenrieder S, Stieber P, Bodenmüller H, Fertig G, Fürst H, Schmeller N, Untch M, Seidel D. Nucleosomes in serum as a marker for cell death. Clin Chem Lab Med 2001, 39:596-605.
32. Ariel IM. Radioactive isotopes for adjuvant cancer therapy; animal experimentation and preliminary results in human application. Arch Surg 1964, 89:244-249.
33. Cianni R, Urigo C, Notarianni E, Saltarelli A, Salvatori R, Pasqualini V, Dornbusch T, Cortesi E. Selective internal radiation therapy with SIR-spheres for the treatment of unresectable colorectal hepatic metastases. Cardiovasc Intervent Radiol 2009, 32:1179-1186.
34. Gray B, Van Hazel G, Hope M, Burton M, Moroz P, Anderson J, Gebski V. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol 2001, 12:1711-1720.
35. Cade D. FOLFOX plus SIR-spheres microspheres versus FOLFOX alone in patients with liver metastases from primary colorectal cancer (SIRFLOX). Clinical trials identification number NCT00724503 , http://clinicaltrials.gov
36. Duffy MJ, van Dalen A, Haglund C, Hansson L, Holinski-Feder E, Klapdor R, Lamerz R, Peltomaki P, Sturgeon C, Topolcan O. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer 2007, 43:1348-1360.
37. Reiter W, Stieber P, Reuter C, Nagel D, Lau-Werner U, Lamerz R. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer. Anticancer Res 2000, 20:5195-5198.
38. Goldstein MJ, Mitchell EP. Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Invest 2005, 23:338-351.
39. Hoffmann RT, Jakobs TF, Kubisch CH, Stemmler HJ, Trumm C, Tatsch K, Helmberger TK, Reiser MF. Radiofrequency ablation after selective internal radiation therapy with Yttrium90 microspheres in metastatic liver disease-Is it feasible?. Eur J Radiol 2010, 74:199-205.
40. McMillan DC, Canna K, McArdle CS. Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg 2003, 90:215-219.
41. Holdenrieder S, Stieber P. Circulating apoptotic markers in the management of non-small cell lung cancer. Cancer Biomark 2010, 6:197-210.
42. Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brünner N, Chan DW, Babaian R, Bast RC J, Dowell B, Esteva FJ, Haglund C, Harbeck N. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 2008, 54:e11-79.
43. Holdenrieder S, Stieber P, Bodenmüller H, Busch M, Fertig G, Fürst H, Schalhorn A, Schmeller N, Untch M, Seidel D. Nucleosomes in serum of patients with benign and malignant diseases. Int J Cancer 2001, 95:114-120.
44. Holdenrieder S, Nagel D, Schalhorn A, Heinemann V, Wilkowski R, von Pawel J, Raith H, Feldmann K, Kremer AE, Müller S, Geiger S, Hamann GF, Seidel D, Stieber P. Clinical relevance of circulating nucleosomes in cancer. Ann N Y Acad Sci 2008, 1137:180-189.
45. Meyn RE, Stephens LC, Ang KK, Hunter NR, Brock WA, Milas L, Peters LJ. Heterogeneity in the development of apoptosis in irradiated murine tumours of different histologies. Int J Radiat Biol 1993, 64:583-591.
46. Molina R, Holdenrieder S, Auge JM, Stieber P. Diagnostic relevance of circulating biomarkers in patients with lung cancer. Cancer Biomark 2010, 6:163-178.
47. Barak V, Holdenrieder S, Nisman B, Stieber P. Relevance of circulating biomarkers for the therapy monitoring and follow-up investigations in patients with non-small cell lung cancer. Cancer Biomark 2010, 6:191-196.
48. Crozier JE, McKee RF, McArdle CS, Angerson WJ, Anderson JH, Horgan PG, McMillan DC. The presence of a systemic inflammatory response predicts poorer survival in patients receiving adjuvant 5-FU chemotherapy following potentially curative resection for colorectal cancer. Br J Cancer 2006, 94:1833-1836.
49. Riaz A, Kulik L, Lewandowski RJ, Ryu RK, Giakoumis Spear G, Mulcahy MF, Abecassis M, Baker T, Gates V, Nayar R, Miller FH, Sato KT. Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatol 2009, 49:1185-1193.
50. Atassi B, Bangash AK, Bahrani A, Pizzi G, Lewandowski RJ, Ryu RK, Sato KT, Gates VL, Mulcahy MF, Kulik L, Miller F, Yaghmai V. Multimodality imaging following 90Y radioembolization: a comprehensive review and pictorial essay. Radiogr 2008, 28:81-99.